Fig. 4.

17-AAG accelerates in vivo tumor growth of prostate cancer cells in bone and this is abrogated by mechanistically distinct inhibitors of osteoclast-mediated bone resorption. (A) Typical tumor signal intensity in mice 2.5 weeks after intratibial inoculation. The effect of (B) dasatinib (Src inhibitor), (C) alendronate (bisphosphonate), and (D) reveromycin A on 17-AAG-induced PC-3M-luc growth in bone is graphically displayed. The control group was treated with DMSO i.p. twice weekly. Luciferase activity was detected and quantified by using a bioluminescent IVIS Imaging System. Data are expressed as means ± SEM. *, P < 0.05 vs. control.